CL2011002662A1 - Solid preparation comprising i) acid 2-ethoxy-1 - (cyclohexyloxycarbonyloxy) ethyl-2-ethoxy-1 - [[2- (1h-tetrazol-5- yl) biphenyl-4-yl] biphenyl-4- ] methyl] benzimidazol-7-carboxylic acid, and 2-ethoxy-1 - [[2- (4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl] -1h-benzimidazol-7- carboxylic acid, ii) mannitol, and iii) amlodipine. - Google Patents
Solid preparation comprising i) acid 2-ethoxy-1 - (cyclohexyloxycarbonyloxy) ethyl-2-ethoxy-1 - [[2- (1h-tetrazol-5- yl) biphenyl-4-yl] biphenyl-4- ] methyl] benzimidazol-7-carboxylic acid, and 2-ethoxy-1 - [[2- (4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl] -1h-benzimidazol-7- carboxylic acid, ii) mannitol, and iii) amlodipine.Info
- Publication number
- CL2011002662A1 CL2011002662A1 CL2011002662A CL2011002662A CL2011002662A1 CL 2011002662 A1 CL2011002662 A1 CL 2011002662A1 CL 2011002662 A CL2011002662 A CL 2011002662A CL 2011002662 A CL2011002662 A CL 2011002662A CL 2011002662 A1 CL2011002662 A1 CL 2011002662A1
- Authority
- CL
- Chile
- Prior art keywords
- biphenyl
- ethoxy
- methyl
- benzimidazol
- carboxylic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Preparación sólida que comprende: i) Compuestos derivados de 1-(bifenil-4-il-metil)-bencimidazol, ii) Un alcohol de azúcar y iii) Un antagonista de calcio.Solid preparation comprising: i) Compounds derived from 1- (biphenyl-4-yl-methyl) -benzimidazole, ii) A sugar alcohol and iii) A calcium antagonist.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009111381 | 2009-04-30 | ||
JP2010068625 | 2010-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011002662A1 true CL2011002662A1 (en) | 2012-06-15 |
Family
ID=43032637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011002662A CL2011002662A1 (en) | 2009-04-30 | 2011-10-26 | Solid preparation comprising i) acid 2-ethoxy-1 - (cyclohexyloxycarbonyloxy) ethyl-2-ethoxy-1 - [[2- (1h-tetrazol-5- yl) biphenyl-4-yl] biphenyl-4- ] methyl] benzimidazol-7-carboxylic acid, and 2-ethoxy-1 - [[2- (4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl] -1h-benzimidazol-7- carboxylic acid, ii) mannitol, and iii) amlodipine. |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP2424501A2 (en) |
JP (1) | JP5666471B2 (en) |
KR (1) | KR101797776B1 (en) |
CN (1) | CN102481248B (en) |
AU (1) | AU2010242308A1 (en) |
BR (1) | BRPI1014388A2 (en) |
CA (1) | CA2760073A1 (en) |
CL (1) | CL2011002662A1 (en) |
CO (1) | CO6470841A2 (en) |
CR (1) | CR20110581A (en) |
DO (1) | DOP2011000329A (en) |
EA (1) | EA201171329A1 (en) |
EC (1) | ECSP11011494A (en) |
GE (1) | GEP20135940B (en) |
IL (1) | IL215962A0 (en) |
MA (1) | MA33280B1 (en) |
MX (1) | MX2011011011A (en) |
MY (1) | MY158158A (en) |
NZ (1) | NZ596395A (en) |
PE (1) | PE20120315A1 (en) |
SG (1) | SG175794A1 (en) |
TW (1) | TWI438201B (en) |
WO (1) | WO2010126168A2 (en) |
ZA (1) | ZA201108375B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL236001B1 (en) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition, |
KR101535586B1 (en) * | 2014-08-01 | 2015-07-09 | 에스케이케미칼주식회사 | Pharmaceutical preparation comprising amorphous or metastable form of rivaroxaban |
KR101806004B1 (en) * | 2015-01-30 | 2017-12-08 | 씨제이헬스케어 주식회사 | A pharmaceutical composition comprising candesartan and amlodipine |
CN106668016B (en) * | 2015-11-11 | 2020-06-23 | 江苏先声药业有限公司 | Solid preparation of azilsartan and amlodipine besylate composition and preparation method thereof |
JP2017210435A (en) * | 2016-05-25 | 2017-11-30 | ダイト株式会社 | Method for producing irbesartan and amlodipine besylate-containing tablet |
JP2019001782A (en) * | 2017-06-14 | 2019-01-10 | 東和薬品株式会社 | Bilayer tablet |
JP7101464B2 (en) * | 2017-09-28 | 2022-07-15 | エルメッド株式会社 | A method for improving the quality of azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof, and azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof and a method for producing the same. |
CN108210472A (en) * | 2017-12-15 | 2018-06-29 | 蚌埠丰原医药科技发展有限公司 | A kind of Cilnidipine solid dispersions tablet and preparation method thereof |
CN108685925B (en) * | 2018-05-15 | 2019-12-06 | 徐州医科大学 | application of compound AB-38b in preparation of medicine for treating diabetic nephropathy |
JP2020075869A (en) * | 2018-11-05 | 2020-05-21 | 日本ケミファ株式会社 | Tablet containing angiotensin ii receptor antagonist and calcium antagonist as active ingredients |
JP7206872B2 (en) * | 2018-12-07 | 2023-01-18 | ニプロ株式会社 | Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same |
JP2020090471A (en) * | 2018-12-07 | 2020-06-11 | ニプロ株式会社 | Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same |
JP7441105B2 (en) | 2020-03-31 | 2024-02-29 | 日本ジェネリック株式会社 | Film-coated tablets containing azilsartan and amlodipine besilate |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2814513B2 (en) * | 1988-02-03 | 1998-10-22 | 吉富製薬株式会社 | Pharmaceutical composition with improved dissolution |
JP3057471B2 (en) * | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | Agent for preventing or treating angiotensin II-mediated diseases |
CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | Sulfone derivatives, process for their production and use thereof |
EP1369130A1 (en) * | 2001-03-16 | 2003-12-10 | Takeda Chemical Industries, Ltd. | Process for producing sustained release preparation |
WO2003047573A1 (en) * | 2001-12-03 | 2003-06-12 | Takeda Chemical Industries, Ltd. | Insulin resistance improving agents |
AU2003235395A1 (en) * | 2002-05-22 | 2003-12-02 | Shionogi And Co., Ltd. | Pharmaceutical preparation improved in dissolving property of drug slightly soluble in water |
WO2004048363A1 (en) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
WO2005030740A1 (en) | 2003-09-30 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
JP4769082B2 (en) | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | Urea derivatives, their production and use |
TWI396686B (en) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | Cyclic amide derivative, and its production and use |
JP2006321726A (en) * | 2005-05-17 | 2006-11-30 | Sysmex Corp | Method for controlling elution property of tablet |
KR101384841B1 (en) * | 2005-06-27 | 2014-04-15 | 다이이찌 산쿄 가부시키가이샤 | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
JP5063370B2 (en) * | 2005-06-27 | 2012-10-31 | 第一三共株式会社 | Method for preparing wet granulated pharmaceutical |
DE102005031577A1 (en) * | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmaceutical dosage forms containing a combination of nifedipine and / or nisoldipine and an angiotensin II antagonist |
WO2008129846A1 (en) * | 2007-03-29 | 2008-10-30 | Daiichi Sankyo Company, Limited | Pharmaceutical composition |
TW201014850A (en) * | 2008-09-25 | 2010-04-16 | Takeda Pharmaceutical | Solid pharmaceutical composition |
-
2010
- 2010-04-28 MX MX2011011011A patent/MX2011011011A/en not_active Application Discontinuation
- 2010-04-28 SG SG2011078391A patent/SG175794A1/en unknown
- 2010-04-28 MA MA34358A patent/MA33280B1/en unknown
- 2010-04-28 KR KR1020117027421A patent/KR101797776B1/en active IP Right Grant
- 2010-04-28 PE PE2011001882A patent/PE20120315A1/en not_active Application Discontinuation
- 2010-04-28 EP EP10719654A patent/EP2424501A2/en not_active Withdrawn
- 2010-04-28 JP JP2011545129A patent/JP5666471B2/en active Active
- 2010-04-28 MY MYPI2011005206A patent/MY158158A/en unknown
- 2010-04-28 BR BRPI1014388A patent/BRPI1014388A2/en not_active IP Right Cessation
- 2010-04-28 GE GEAP201012480A patent/GEP20135940B/en unknown
- 2010-04-28 NZ NZ596395A patent/NZ596395A/en not_active IP Right Cessation
- 2010-04-28 AU AU2010242308A patent/AU2010242308A1/en not_active Abandoned
- 2010-04-28 TW TW099113442A patent/TWI438201B/en active
- 2010-04-28 EA EA201171329A patent/EA201171329A1/en unknown
- 2010-04-28 CA CA2760073A patent/CA2760073A1/en not_active Abandoned
- 2010-04-28 CN CN2010800289702A patent/CN102481248B/en active Active
- 2010-04-28 WO PCT/JP2010/057923 patent/WO2010126168A2/en active Application Filing
-
2011
- 2011-10-26 DO DO2011000329A patent/DOP2011000329A/en unknown
- 2011-10-26 CL CL2011002662A patent/CL2011002662A1/en unknown
- 2011-10-26 IL IL215962A patent/IL215962A0/en unknown
- 2011-11-08 CR CR20110581A patent/CR20110581A/en unknown
- 2011-11-15 ZA ZA2011/08375A patent/ZA201108375B/en unknown
- 2011-11-30 EC EC2011011494A patent/ECSP11011494A/en unknown
- 2011-11-30 CO CO11164599A patent/CO6470841A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2010242308A1 (en) | 2011-12-01 |
PE20120315A1 (en) | 2012-04-07 |
DOP2011000329A (en) | 2011-11-15 |
TW201041873A (en) | 2010-12-01 |
CA2760073A1 (en) | 2010-11-04 |
MX2011011011A (en) | 2011-11-02 |
JP2012525323A (en) | 2012-10-22 |
CN102481248B (en) | 2013-12-11 |
JP5666471B2 (en) | 2015-02-12 |
EP2424501A2 (en) | 2012-03-07 |
KR20120026060A (en) | 2012-03-16 |
TWI438201B (en) | 2014-05-21 |
CO6470841A2 (en) | 2012-06-29 |
NZ596395A (en) | 2013-06-28 |
WO2010126168A3 (en) | 2011-03-03 |
MA33280B1 (en) | 2012-05-02 |
SG175794A1 (en) | 2011-12-29 |
IL215962A0 (en) | 2012-01-31 |
ZA201108375B (en) | 2013-01-30 |
WO2010126168A2 (en) | 2010-11-04 |
ECSP11011494A (en) | 2011-12-30 |
EA201171329A1 (en) | 2012-05-30 |
CN102481248A (en) | 2012-05-30 |
BRPI1014388A2 (en) | 2016-04-05 |
KR101797776B1 (en) | 2017-11-14 |
CR20110581A (en) | 2012-01-19 |
GEP20135940B (en) | 2013-10-10 |
MY158158A (en) | 2016-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011002662A1 (en) | Solid preparation comprising i) acid 2-ethoxy-1 - (cyclohexyloxycarbonyloxy) ethyl-2-ethoxy-1 - [[2- (1h-tetrazol-5- yl) biphenyl-4-yl] biphenyl-4- ] methyl] benzimidazol-7-carboxylic acid, and 2-ethoxy-1 - [[2- (4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl] -1h-benzimidazol-7- carboxylic acid, ii) mannitol, and iii) amlodipine. | |
AR094588A2 (en) | PROCESS FOR OBTAINING A COMPOSITE DERIVED FROM BENZIMIDAZOL AND PHARMACEUTICAL COMPOSITION | |
HUP1300730A2 (en) | A method of preparing 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl- 4-yl)methyl)-1h-benzo[d]imidazole-7-carboxylates and conversion thereof to azilsartan | |
FR18C1020I2 (en) | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3-YL]PHENYL}-2H-INDAZOLE-7-CARBOXAMIDE | |
WO2012107814A8 (en) | An improved process for the preparation of azilsartan medoxomil | |
DK3170818T3 (en) | SOLID FORMS OF 3- (6- (1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-YL) CYCLOPROPANCARBOXAMIDO) -3-METHYLPYRIDIN-2-YL) BENZOIC ACID | |
CL2011000625A1 (en) | Solid preparation comprising 2-ethoxy-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1h-benzimidazole (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl carboxylate, a ph regulating agent and a calcium antagonist compound; and methods for using and improving dissolution of the compound in the solid preparation. | |
PE20190342A1 (en) | ACTIVE COMPOUND COMBINATIONS | |
ATE526325T1 (en) | SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS | |
FR2939113B1 (en) | SYSTEM FOR AUTOMATICALLY PLACING LOADS | |
HUP1300733A2 (en) | A method of preparing 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl- 4-yl)methyl)-1h-benzo[d]imidazole-7-carboxylates and conversion thereof to azilsartan | |
DK2094694T3 (en) | Quiniclidine derivatives of (hetero) acrylic cycloheptane carboxylic acid as muscarinic receptor antagonists | |
IL228153A (en) | Method of manufacturing 2-ethoxy-1-((2'-((hydroxyamino) iminomethyl)biphenyl-4- yl)methyl)-1h-benzo [d] imidazole-7-carboxylic acid and its esters | |
EP2253318A4 (en) | Improvement of dissolvability of preparation containing olmesartan medoxomil | |
ECSP066727A (en) | USEFUL COUPLING REACTIONS IN THE PREPARATION OF DERIVATIVES OF (1H-TETRAZOL-5-IL) -BIFENYL | |
BRPI0821315A2 (en) | benzimidazole compounds | |
EA201390457A1 (en) | POLYMORPHES AND SALTS 6- (1H-INDOL-4-IL) -4- (5 - {[4- (1-METHYLETHYL) -1-PIPERASINYL] METHYL} -1,3-OXAZOL-2-IL) -1H- INDAZOLE AS PI3K INHIBITORS FOR USE IN TREATMENT, FOR EXAMPLE RESPIRATORY DISORDERS | |
HK1160642A1 (en) | Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists via | |
CL2011000138A1 (en) | Use of 1- {4- [1- (4-cyclohexyl-3-trifluoro-methyl-benzyloxyimino) -ethyl-2-ethyl-benzyl} -azetidine-3-carboxylic acid compounds for the preparation of a medicament for preventing, inhibiting or treat an inflammatory condition selected from polymyositis or dermatomyositis. | |
WO2011007368A3 (en) | An improved process for preparation of olmesartan | |
WO2012056294A8 (en) | An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-l-valine | |
IL210141A0 (en) | Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1 h-pyrrole-3-carboxamide | |
SI2139866T1 (en) | CRYSTALLINE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYL 1-((2'-CYANOBIPHENYL-4-YL)METHYL)-2-ETHOXY-1H-BENZO?áD?åIMIDAZOLE-7-CARBOXYLATE AND A PROCESS FOR ITS PREPARATION | |
ATE546448T1 (en) | UROTENSIN II RECEPTOR ANTAGONISTS | |
WO2010116380A3 (en) | A one pot process for preparing 2-butyl-3-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4] non-1-en-4-one (irbesartan) |